Oncolytics Biotech Inc ONCY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
-
Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer
-
Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
-
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
-
Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
-
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
-
Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
-
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
Trading Information
- Previous Close Price
- $0.47
- Day Range
- $0.46–0.50
- 52-Week Range
- $0.44–1.32
- Bid/Ask
- $0.46 / $0.48
- Shares Outstanding
- 131.12M
- Market Cap
- $60.62M
- Volume/Avg
- 859,328 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 29
Valuation
|
Metric
|
ONCY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ONCY
|
|---|---|
Quick Ratio | 1.02 |
Current Ratio | 1.35 |
Interest Coverage | — |
Quick Ratio
ONCY
Profitability
|
Metric
|
ONCY
|
|---|---|
Return on Assets (Normalized) | −349.07% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ONCY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|vJ?x&#^ | LOCK|YJ%@> | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|c&?<vM | LOCK|T!&%< | $84B | |||
| Moderna Inc
MRNA
| LOCK|@^hDDJ | LOCK|Zf | $83B | |||
| argenx SE ADR
ARGX
| LOCK|^%gjT!? | LOCK|KwH | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|w$Y!&^ | LOCK|wR | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|jt$y#> | LOCK|<<<BS | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|JGN&&mQV | LOCK|@<Ws | $29B | |||
| Incyte Corp
INCY
| LOCK|#%Y?W%? | LOCK|!J | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|@MWl@! | LOCK|$p& | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Kzd$srY | LOCK|$d^ | $14B |
United States